Xizang Weixinkang Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 219 million yuan, a year-on-year decrease of 9.9%

According to the Zhitong Finance APP, Xizang Weixinkang Pharmaceutical disclosed its third-quarter report for 2025. The company achieved revenue of 862 million yuan in the first three quarters, a year-on-year decrease of 13.27%; net profit attributable to the parent company was 219 million yuan, a year-on-year decrease of 9.9%; net profit excluding non-recurring gains and losses was 169 million yuan, a year-on-year decrease of 14.01%; basic earnings per share were 0.51 yuan

Xizang Weixinkang Pharmaceutical: Net profit of 183 million yuan in the first half of 2025, a year-on-year increase of 11.82%

Xizang Weixinkang Pharmaceutical announced that in the first half of 2025, operating revenue was 586 million yuan, a year-on-year decrease of 7.43%. Net profit was 183 million yuan, a year-on-year increase of 11.82%

Pharmaceutical stocks continue to be strong, FUSHILAI hits the 20% limit up, Tuoxin Pharmaceutical and Cosunter rise over 10%, Xizang Weixinkang Pharmaceutical, MEDISAN and several other stocks hit the limit up

Xizang Weixinkang Pharmaceutical: Received government subsidies related to revenue amounting to 34.3437 million yuan

On the evening of June 30, Xizang Weixinkang Pharmaceutical announced that on March 27 and June 30, the company and its wholly-owned subsidiary, Xizang Zhongwei Chengkang Pharmaceutical Co., Ltd., received a total of 34.3437 million yuan in corporate development funds for 2024. This government subsidy is related to revenue and accounts for 13.95% of the company's net profit for the 2024 fiscal year

Xizang Weixinkang Pharmaceutical: Cooperative product injectable multivitamins (12) passed the consistency evaluation of generic drugs

Xizang Weixinkang Pharmaceutical announced that its cooperative manufacturer Pude Pharmaceutical has received the drug supplementary application notice approved by the National Medical Products Administration for injectable multivitamins (12), which has passed the consistency evaluation of quality and efficacy for generic drugs. Injectable multivitamins (12) are the company's core products, suitable for adult patients and children over 11 years old who require intravenous vitamin supplementation